| Asthma
Alvesco vs Breyna
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Alvesco vs Breyna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreyna has a higher rate of injection site reactions vs Alvesco based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breyna but not Alvesco, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alvesco
Breyna
At A Glance
Oral inhalation
Twice daily
Inhaled corticosteroid
Oral inhalation
Twice daily
ICS/LABA combination
Indications
- Asthma
- Asthma
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Asthma 80 mcg twice daily by oral inhalation as starting dose for patients on bronchodilators alone or inhaled corticosteroids, up to 320 mcg twice daily; patients previously on oral corticosteroids start at 320 mcg twice daily (maximum).
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Known hypersensitivity to ciclesonide or any ingredient of ALVESCO
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Hypersensitivity to any ingredient in BREYNA
Adverse Reactions
Most common (>=3%) Headache, nasopharyngitis, sinusitis, pharyngolaryngeal pain, upper respiratory infection, arthralgia, nasal congestion, pain in extremity, back pain
Serious Oropharyngeal candidiasis, immunosuppression and risk of infections, hypercorticism, adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma, cataracts
Postmarketing Immediate or delayed hypersensitivity reactions including angioedema with swelling of lips, tongue, and pharynx
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Pharmacology
Ciclesonide is an inhaled corticosteroid prodrug hydrolyzed by esterases to its active metabolite des-ciclesonide, which binds glucocorticoid receptors with 120-fold greater affinity than the parent compound and exerts broad anti-inflammatory activity against mast cells, eosinophils, lymphocytes, macrophages, and neutrophils involved in the asthmatic response.
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alvesco
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Breyna
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Alvesco
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (3/8)
Breyna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Alvesco
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (3/3)
Breyna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alvesco.
No savings programs available for Breyna.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlvescoView full Alvesco profile
BreynaView full Breyna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.